Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03507543
Other study ID # IMP4297-2016-AU01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 3, 2017
Est. completion date March 17, 2021

Study information

Verified date March 2021
Source Impact Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.


Description:

This is a phase 1, First-In-Human, open label study, trialing a new PARP inhibitor medication IMP4297 in participants with advanced solid tumour. Six different dosage cohorts 2mg, 6mg, 10mg, 20mg, 30mg and 40mg will be used to establish the maximum tolerated dosage. First participant in each dosing cohort will be administered one dose of IMP4297 capsule, followed by a wash out period of at least 5 half-lives or 7 days. Safety information such as pathology result or adverse events experienced will be collected following first dosing. This will be reviewed by the a safety review committee that is made up of the Principal Investigator, Medical Monitor, the study Sponsor and a representative from the Clinical Research Organisation, which will collectively determine if it is safe to proceed to continue with the next scheduled dosing cohort. Participant will proceed with repeat once daily dose at the same dose level for 3 weeks. Each repeat dose treatment cycle will be composed of 3 weeks (Day 1 to Day 21). IMP4297 will be administered by participants at home. Participants will be instructed to bring unused IMP4297 capsules with them to each visit for trial staff to review and confirm amount of IMP4297capsules taken since the last visit. The administration of the IMP4297 capsules will be recorded. Study drug compliance will be assessed using these records in conjunction with a count of unused IMP4297 capsules. Participants who are benefiting from IMP4297 may have the possibility of treatment beyond 1 year at the investigator's discretion. Participants who experience disease progression or unacceptable side effects, are not compliant with study protocol or in the opinion of the investigator will have IMP4297 administration discontinued and study participation will be terminated.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date March 17, 2021
Est. primary completion date September 24, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed Informed Consent Form 2. Age greater than or equal to 18 years 3. Histologically or cytologically documented, incurable, advanced solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy 4. Evaluable or measurable disease per RECIST 1.1 5. ECOG performance status of 0 or 1 6. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred. Exclusion Criteria: 1. Inadequate haematologic and organ function, defined by the following (haematologic parameters must be assessed greater than or equal to 14 days after a prior treatment, if any): 1. Absolute neutrophil count <1500 cells/uL 2. Haemoglobin <9 g/dL 3. Total bilirubin >1.5 x the ULN, with documented liver metastases total bilirubin >3 x the ULN . 4. AST and/or ALT >2.5 x the ULN, with documented liver metastases AST and/or ALT levels > 5 x the ULN. 5. Serum creatinine > 1.5 x the ULN, or creatinine clearance < 50 mL/min based on a documented 24-hour urine collection. 6. International normalized ratio (INR) > 1.5 x the ULN or activated partial thromboplastin time (aPTT) >1.5 x the ULN The INR applies only to patients who do not receive therapeutic anti-coagulation. 2. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions: 1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer 2. Hormone-replacement therapy or oral contraceptives 3. Palliative radiation to bone metastases > 2 weeks prior to Day 1 3. Adverse events from prior anti-cancer therapy that have not resolved to CTCAE Grade less than or equal to 1, except for alopecia 4. Clinical significant active infection 5. Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis 6. Known human immunodeficiency virus infection 7. New York Heart Association (NYHA) Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or transient ischemic attack within 6 months prior to Day 1 8. Active or untreated brain metastasis 9. Pregnant (positive pregnancy test) or lactating women 10. Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment 11. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease 12. Inability to comply with study and follow-up procedures 13. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

Study Design


Intervention

Drug:
IMP4297
The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Locations

Country Name City State
Australia Blacktown Hospital Blacktown New South Wales
Australia St George Private Hospital Kogarah New South Wales
Australia Nucleus Network Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Impact Therapeutics, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors. Evaluate the TEAE (treatment-emergent adverse event) of IMP4297 Each visit after IMP4297 administrated (through study completion, an average of 10 months)
Primary The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297. Evaluate DLT and determine the MTD Within 28 days after IMP4297 administrated
Secondary Area Under Curve [AUClast, AUCINF and AUCtau] Within 7 days after firstly single dose administrated
Secondary Area Under Curve [AUClast, AUCINF and AUCtau] Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
Secondary Maximum plasma concentration (Cmax) Within 7 days after firstly single dose administrated
Secondary Maximum plasma concentration (Cmax) Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
Secondary Time at which Cmax occurred (Tmax) Within 7 days after firstly single dose administrated
Secondary Time at which Cmax occurred (Tmax) Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
Secondary Trough Concentrations (Ctrough) Within 7 days after firstly single dose administrated
Secondary Trough Concentrations (Ctrough) Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
Secondary Clearance (CL/F) Within 7 days after firstly single dose administrated
Secondary Clearance (CL/F) Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
Secondary Volume of distribution (Vd/F) Within 7 days after firstly single dose administrated
Secondary Volume of distribution (Vd/F) Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A